U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 42 results

ZINC CATION

MORE DETAILS

  13S1S8SF37

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZIRCONIUM CARBONATE

MORE DETAILS

QLH2275OWS

Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)

ZINC DIBUTYRATE

MORE DETAILS

  VA6XH8E3JX

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC CITRATE DIHYDRATE

MORE DETAILS

  021IBV57IL

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC SUCCINATE

MORE DETAILS

  IY01B595GR

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC OROTATE DIHYDRATE

MORE DETAILS

  2R18GO895S

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC MONOCARBONATE

MORE DETAILS

  K8290PTQ4F

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

ZINC NITRIDE

MORE DETAILS

  7OOJ6UE14L

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

AMMONIUM PENTACHLOROZINCATE

MORE DETAILS

  3ILV18PW3Y

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

AMMONIUM TETRACHLOROZINCATE

MORE DETAILS

  NK9T00M5VV

Status:
US Approved OTC
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methotrexate
38
respiratory burst
39
Streptococcus mutans
41
transformed cell apoptotic process
104
ultraviolet B-induced damage
38
T cell mediated immunity
40
Zinc transporter ZIP1
38
Zinc transporter ZIP2
38
Conditions:
Renal insufficiency
40
Ulcerative colitis
125
Unknown
2,596
Caries
43
Breast cancer
432
Acute myeloid leukemia
141
Zinc deficiency
39
Poison Ivy dermatitis
38
Diaper dermatitis
38
Unknown
2,596
Dysgeusia
38
Mucositis
39
Gastrointestinal disorders
94
Unknown
2,596
Unknown
2,596
There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966